Personal information

Verified email domains

Activities

Employment (1)

RIKEN: Wako, JP

2024-04-01 to present | Postdoctoral Researcher (Cancer Translational Research Team)
Employment
Source: Self-asserted source
Hiromi Matsumoto

Education and qualifications (1)

Yokohama City University: Yokohama, JP

2017-04-01 to 2023-03-31 (Graduate school of medicine)
Education
Source: Self-asserted source
Hiromi Matsumoto

Works (8)

High red blood cell distribution width attenuates the effectiveness of Immune checkpoint inhibitor therapy: An exploratory study using a clinical data warehouse

PLOS ONE
2024-08-01 | Journal article
Contributors: Hiromi Matsumoto; Santosh K. Patnaik; Taichi Fukushima; Nobuaki Kobayashi; Yuuki Higashino; Suguru Muraoka; Yukiko Ohtsu; Momo Hirata; Kohei Somekawa; Ayami Kaneko et al.
Source: check_circle
Crossref

Geographic and economic influences on benralizumab prescribing for severe asthma in Japan.

Scientific reports
2024-07-02 | Journal article
Contributors: Kobayashi N; Matsumoto H; Somekawa K; Kaneko A; Fukuda N; Muraoka S; Ohtsu Y; Hirata M; Nagasawa R; Kubo S et al.
Source: Self-asserted source
Hiromi Matsumoto

Influence of age, IGRA results, and inflammatory markers on mortality in hospitalized tuberculosis patients

Journal of Infection and Chemotherapy
2024-01 | Journal article
Contributors: Nobuaki Kobayashi; Katsushi Tanaka; Suguru Muraoka; Kohei Somekawa; Ayami Kaneko; Sousuke Kubo; Hiromi Matsumoto; Hiroaki Fujii; Keisuke Watanabe; Nobuyuki Horita et al.
Source: check_circle
Crossref

Tailoring Therapeutic Strategies in Non-Small-Cell Lung Cancer: The Role of Genetic Mutations and Programmed Death Ligand-1 Expression in Survival Outcomes

Cancers
2023-10-31 | Journal article
Contributors: Nobuaki Kobayashi; Kenji Miura; Ayami Kaneko; Hiromi Matsumoto; Kohei Somekawa; Tomofumi Hirose; Yukihito Kajita; Anna Tanaka; Shuhei Teranishi; Yu Sairenji et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Regional differences in epidermal growth factor receptor-tyrosine kinase inhibitor therapy in lung cancer treatment using a national database in Japan

Scientific Reports
2023-03-30 | Journal article
Part of ISSN: 2045-2322
Contributors: Hiromi Matsumoto; Nobuaki Kobayashi; Satoru Shinoda; Atsushi Goto; Ayami Kaneko; Nobuhiko Fukuda; Chisato Kamimaki; Sousuke Kubo; Keisuke Watanabe; Nobuyuki Horita et al.
Source: Self-asserted source
Hiromi Matsumoto
grade
Preferred source (of 2)‎

Adverse events induced by durvalumab and tremelimumab combination regimens: a systematic review and meta-analysis

Therapeutic Advances in Medical Oncology
2023-01 | Journal article
Contributors: Hiromi Matsumoto; Kohei Somekawa; Nobuyuki Horita; Suguru Ueda; Megumi Kaneko; Ayami Kaneko; Nobuhiko Fukuda; Ami Izawa; Chisato Kamimaki; Katsushi Tanaka et al.
Source: check_circle
Crossref

Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial

Thoracic Cancer
2022-01 | Journal article
Part of ISSN: 1759-7706
Part of ISSN: 1759-7714
Contributors: Hiromi Matsumoto; Nobuaki Kobayashi; Kohei Somekawa; Nobuhiko Fukuda; Ayami Kaneko; Chisato Kamimaki; Sousuke Kubo; Katsushi Tanaka; Yoichi Tagami; Shuhei Teranishi et al.
Source: Self-asserted source
Hiromi Matsumoto

Disease control and objective responsive rates in randomized phase II trials evaluating non-first-line chemotherapy for non-small cell lung cancer: a systematic review of 74 trials

Translational Lung Cancer Research
2021-05 | Journal article
Part of ISSN: 2218-6751
Part of ISSN: 2226-4477
Contributors: Hiromi Matsumoto; Nobuyuki Horita; Kentaro Ito; Risa Ebina-Shibuya; Yu Hara; Nobuaki Kobayashi; Takeshi Kaneko
Source: Self-asserted source
Hiromi Matsumoto